[go: up one dir, main page]

TNSN06138A1 - Inhibitors of the mutant form of kit - Google Patents

Inhibitors of the mutant form of kit

Info

Publication number
TNSN06138A1
TNSN06138A1 TNP2006000138A TNSN06138A TNSN06138A1 TN SN06138 A1 TNSN06138 A1 TN SN06138A1 TN P2006000138 A TNP2006000138 A TN P2006000138A TN SN06138 A TNSN06138 A TN SN06138A TN SN06138 A1 TNSN06138 A1 TN SN06138A1
Authority
TN
Tunisia
Prior art keywords
kit
inhibitors
mutant
mutant form
midostaurin
Prior art date
Application number
TNP2006000138A
Other languages
English (en)
Inventor
Elisabeth Buchdunger
Doriano Fabbro
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of TNSN06138A1 publication Critical patent/TNSN06138A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/44—Multiple drug resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Saccharide Compounds (AREA)

Abstract

The present invention relates to the treatment of KIT dependent diseases that are characterized by a mutant form of KIT whereby the mutant KIT is identified and an appropriate inhibitor of the mutant KIT selected form midostaurin, vatalanib and compound A is administered.
TNP2006000138A 2003-11-18 2006-05-15 Inhibitors of the mutant form of kit TNSN06138A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US52071403P 2003-11-18 2003-11-18
PCT/EP2004/013045 WO2005049032A1 (fr) 2003-11-18 2004-11-17 Inhibiteurs de la forme mutante du kit

Publications (1)

Publication Number Publication Date
TNSN06138A1 true TNSN06138A1 (fr) 2007-11-15

Family

ID=34619508

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP2006000138A TNSN06138A1 (fr) 2003-11-18 2006-05-15 Inhibitors of the mutant form of kit

Country Status (28)

Country Link
US (3) US8017621B2 (fr)
EP (2) EP1917965A1 (fr)
JP (3) JP4762150B2 (fr)
KR (1) KR101153647B1 (fr)
CN (3) CN102274230B (fr)
AT (1) ATE428426T1 (fr)
AU (1) AU2004290902B2 (fr)
BR (1) BRPI0416680A (fr)
CA (1) CA2546189C (fr)
CY (1) CY1110354T1 (fr)
DE (1) DE602004020654D1 (fr)
DK (1) DK1686997T3 (fr)
ES (1) ES2324917T3 (fr)
HK (1) HK1093680A1 (fr)
HR (1) HRP20090390T1 (fr)
IL (2) IL175578A (fr)
MA (1) MA28176A1 (fr)
MX (1) MXPA06005598A (fr)
NO (1) NO20062694L (fr)
NZ (1) NZ547195A (fr)
PL (1) PL1686997T3 (fr)
PT (1) PT1686997E (fr)
RU (2) RU2405553C1 (fr)
SG (1) SG139747A1 (fr)
SI (1) SI1686997T1 (fr)
TN (1) TNSN06138A1 (fr)
WO (1) WO2005049032A1 (fr)
ZA (1) ZA200603905B (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI324604B (en) 2003-06-18 2010-05-11 Novartis Ag New use of staurosporine derivatives
MXPA06005598A (es) 2003-11-18 2006-08-11 Novartis Ag Inhibidores de la forma mutante de kit.
JP4970262B2 (ja) * 2004-08-31 2012-07-04 ノバルティス アーゲー 消化管間質腫瘍を処置するためのミドスタウリンの使用
EP1879584B1 (fr) * 2005-05-02 2016-06-22 Novartis AG Derives de pyrimidylaminobenzamide contre le syndrome hypereosinophilique
RU2445960C2 (ru) * 2005-05-02 2012-03-27 Новартис Аг Применение производных пиримидиламинобензамида для лечения системного мастоцитоза
GT200600315A (es) * 2005-07-20 2007-03-19 Formas cristalinas de 4-metilo-n-[3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo]-3-(4-pyridina-3-ilo-pirimidina-2-iloamino)-benzamida
RU2429848C2 (ru) * 2005-07-20 2011-09-27 Петер ФАЛЕНТ Композиции для лечения системного мастоцитоза
RU2450814C2 (ru) * 2005-12-06 2012-05-20 Новартис Аг Производные пиримидиламинобензамида, предназначенные для лечения нейрофиброматоза
EP2073803B1 (fr) 2006-10-12 2018-09-19 Astex Therapeutics Limited Combinaisons pharmaceutiques
US8883790B2 (en) 2006-10-12 2014-11-11 Astex Therapeutics Limited Pharmaceutical combinations
US20100298338A1 (en) * 2008-01-23 2010-11-25 Yanfeng Wang Method of optimizing the treatment of proliferative diseases mediated by the tyrosine kinase receptor kit
EP3076966A2 (fr) * 2013-12-02 2016-10-12 BerGenBio AS Utilisation d'inhibiteurs de kinases
CN106188028A (zh) * 2015-05-05 2016-12-07 天津国际生物医药联合研究院 含恶二唑杂环类化合物及其制备方法和应用
WO2018014520A1 (fr) * 2016-07-18 2018-01-25 嘉兴雅康博医学检验所有限公司 Amorces, sondes et kit destinés à être utilisés pour détecter les mutations du gène c-kit
AU2019285066B2 (en) 2018-06-15 2024-06-13 Handa Pharmaceuticals, Inc. Kinase inhibitor salts and compositions thereof
WO2020102095A1 (fr) * 2018-11-12 2020-05-22 Blueprint Medicines Corporation Résistance à l'avapritinib de mutants de kit
US20210308133A1 (en) * 2020-04-06 2021-10-07 The Board Of Regents Of The University Of Texas System Methods and compositions for inhibiting muscle wasting

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5093330A (en) 1987-06-15 1992-03-03 Ciba-Geigy Corporation Staurosporine derivatives substituted at methylamino nitrogen
TW225528B (fr) 1992-04-03 1994-06-21 Ciba Geigy Ag
US5521184A (en) 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
US5612340A (en) 1993-10-01 1997-03-18 Ciba-Geigy Corporation Pyrimidineamine derivatives and processes for the preparation thereof
US5543520A (en) 1993-10-01 1996-08-06 Ciba-Geigy Corporation Pyrimidine derivatives
PL313973A1 (en) 1993-10-12 1996-08-05 Du Pont Merck Pharma 1 n-alkyl-n-arylopyrimidin amines and their derivatives
GB9523675D0 (en) 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
US6815791B1 (en) * 1997-02-10 2004-11-09 Fillfactory Buried, fully depletable, high fill factor photodiodes
CO4950519A1 (es) 1997-02-13 2000-09-01 Novartis Ag Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
GB2325934A (en) 1997-06-03 1998-12-09 Polybiomed Ltd Treating metal surfaces to enhance bio-compatibility and/or physical characteristics
AU7821398A (en) 1997-06-06 1998-12-21 Baylor College Of Medicine The mast cell secretory machine as a target for anti-allergy drug development
US5874603A (en) 1997-07-15 1999-02-23 Gelest, Inc. Branched higher alkylsilanes
CO4940418A1 (es) 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
AU8477998A (en) 1997-11-13 1999-06-07 Histatek, Llc Small peptides and methods for treatment of asthma and inflammation
US20040157855A1 (en) 2001-04-05 2004-08-12 Michael Heinrich Use of n-phenyl-2-pyrimidineamine derivativea against mast cell-based diseases like allergic disorders
CA2452171A1 (fr) 2001-06-29 2003-01-09 Ab Science Utilisation d'inhibiteurs de c-kit puissants, selectifs et non toxiques dans le traitement de la mastocytose
TWI315982B (en) 2001-07-19 2009-10-21 Novartis Ag Combinations comprising epothilones and pharmaceutical uses thereof
US20050095237A1 (en) 2001-12-11 2005-05-05 Emtage Peter C. Methods of therapy and diagnosis using targeting of cells that express P2Y10
US20050118600A1 (en) 2002-03-13 2005-06-02 Yuko Aoki Method for selecting drug sensitivity-determining factors and method for predicting drug sensitivity using the selected factors
GB0215676D0 (en) * 2002-07-05 2002-08-14 Novartis Ag Organic compounds
GB0223341D0 (en) * 2002-10-08 2002-11-13 Groningen Acad Ziekenhuis Organic compounds
TWI324604B (en) 2003-06-18 2010-05-11 Novartis Ag New use of staurosporine derivatives
CA2538523A1 (fr) * 2003-09-19 2005-03-31 Novartis Ag Traitement de tumeurs de stroma du tube digestif avec l'imatinibe et la midostaurine
MXPA06005598A (es) 2003-11-18 2006-08-11 Novartis Ag Inhibidores de la forma mutante de kit.
RU2445960C2 (ru) 2005-05-02 2012-03-27 Новартис Аг Применение производных пиримидиламинобензамида для лечения системного мастоцитоза
CN200998572Y (zh) * 2007-01-29 2008-01-02 深圳市龙岗区坪山宽富高尔夫器具厂 可携带配件的高尔夫球杆头套
JP5448036B2 (ja) * 2009-02-18 2014-03-19 トヨタ自動車株式会社 カルボン酸の製造方法

Also Published As

Publication number Publication date
HK1093680A1 (en) 2007-03-09
DE602004020654D1 (de) 2009-05-28
RU2362562C2 (ru) 2009-07-27
KR20060101761A (ko) 2006-09-26
RU2009110449A (ru) 2010-09-27
JP2013241438A (ja) 2013-12-05
EP1917965A1 (fr) 2008-05-07
US8017621B2 (en) 2011-09-13
BRPI0416680A (pt) 2007-02-13
IL229124A0 (en) 2013-12-31
ZA200603905B (en) 2008-11-26
CN101693031A (zh) 2010-04-14
US20100179179A1 (en) 2010-07-15
AU2004290902B2 (en) 2008-09-25
KR101153647B1 (ko) 2012-06-18
WO2005049032A1 (fr) 2005-06-02
IL175578A0 (en) 2008-04-13
MXPA06005598A (es) 2006-08-11
IL175578A (en) 2013-10-31
CN102274230A (zh) 2011-12-14
JP2007511567A (ja) 2007-05-10
NZ547195A (en) 2010-06-25
SI1686997T1 (sl) 2009-08-31
US20070213317A1 (en) 2007-09-13
ATE428426T1 (de) 2009-05-15
RU2405553C1 (ru) 2010-12-10
US20120157441A1 (en) 2012-06-21
PT1686997E (pt) 2009-07-17
EP1686997A1 (fr) 2006-08-09
CA2546189C (fr) 2013-04-23
SG139747A1 (en) 2008-02-29
CN1882344A (zh) 2006-12-20
NO20062694L (no) 2006-06-12
AU2004290902A1 (en) 2005-06-02
CA2546189A1 (fr) 2005-06-02
PL1686997T3 (pl) 2009-09-30
CN102274230B (zh) 2015-07-01
HRP20090390T1 (hr) 2009-08-31
RU2006121447A (ru) 2008-01-10
JP2011121973A (ja) 2011-06-23
JP4762150B2 (ja) 2011-08-31
US8124611B2 (en) 2012-02-28
MA28176A1 (fr) 2006-09-01
EP1686997B1 (fr) 2009-04-15
CY1110354T1 (el) 2015-04-29
ES2324917T3 (es) 2009-08-19
DK1686997T3 (da) 2009-07-27

Similar Documents

Publication Publication Date Title
TNSN06138A1 (fr) Inhibitors of the mutant form of kit
ATE371656T1 (de) Heteroaryl-pyrimidinderivate als jak-inhibitoren
EA200300906A1 (ru) Новые спиротрициклические производные и их применение в качестве ингибиторов фосфодиэстеразы-7
ATE506354T1 (de) Substituierte arylcyclopropylacetamide als glucokinaseaktivatoren
ATE377004T1 (de) Proteinkinaseinhibitoren
ATE457025T1 (de) Kinaseinhibitoren
PL361404A1 (en) Synergistic combinations comprising a renin inhibitor for cardiovascular diseases
CY1108738T1 (el) Θεραπευτικοι παραγοντες χρησιμοι για την αγωγη του πονου
DE60332604D1 (de) Azolylaminoazine als proteinkinasehemmer
EA200601686A1 (ru) Замещенные производные морфолина и тиоморфолина
DK1206474T3 (da) Sulfonylphenylpyrazolforbindelser anvendelige som cox-2-inhibitorer
EA200700909A1 (ru) Азаиндолкарбоксамиды
EA200601358A1 (ru) Новые ингибиторы химазы
DK1458393T3 (da) Substituerede diketopiperaziner som oxytocinantagonister
DE60329326D1 (de) Tace inhibitoren
ECSP055844A (es) Nuevos compuestos triciclicos
AR039664A1 (es) Composicion farmaceutica que comprende un inhibidor de lipasa y glucomanan
EA200501925A1 (ru) Новый способ синтеза периндоприла и его фармацевтически приемлемых солей
DE602005011267D1 (de) Benzofuran- und benzothiophenderivate, die sich für die behandlung von herzkreislauferkrankungen eignen
SE0002739D0 (sv) New use
DE60322395D1 (de) Antipruritisches mittel
EA200600455A1 (ru) Новый способ синтеза периндоприла и его фармацевтически приемлемых солей
EA200600456A1 (ru) Новый способ синтеза периндоприла и его фармацевтически приемлемых солей
DK1553938T3 (da) Anvendelse af epothilonderivater til behandling af hyperparathyroidisme
EA200600249A1 (ru) Новый способ синтеза периндоприла и его фармацевтически приемлемых солей